Bristol's HCV Bump Catalyzes Strong Quarter, But Not Expected To Last

Daklinza has been part of the standard of care in genotype 3 HCV, but the launch of Gilead's Epclusa and an EU ramp-up of Merck's Zepatier are expected to erode that over time.

Most attention Bristol-Myers Squibb Co. gets these days centers on its pacesetting immuno-oncology franchise, but the pharma's 17% sales growth reported July 28 stemmed as much from increased sales of Orencia and Eliquis, as well as a surprising uptick for its hepatitis C drug Daklinza (daclatasvir). Despite the consensus-beating quarterly revenue for the NS5A inhibitor, however, Bristol conceded that newer competition is likely to erode its HCV sales quickly.

The anti-PD-1 stalwart Opdivo (nivolumab) was Bristol's top-seller during the second quarter, the New York-based pharma reported during a July...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip